Researchers at the University of California, Santa Cruz have found a genetic dimmer switch that decides whether mice survive sepsis: Gaplinc, a long non-coding RNA molecule inside macrophages, the immune cells that first confront an infection. When the team removed Gaplinc entirely, 100 percent of the mice survived lethal levels of bacterial toxin. The finding, published in the Proceedings of the National Academy of Sciences (PNAS) and announced on 16 November 2026, points to a new direction for Gaplinc sepsis treatment research: fine-tuning the body’s metabolic resilience rather than shutting the immune system down. The work is in mice, and no human treatment exists yet.

Key takeaways

  • Gaplinc is a long non-coding RNA inside macrophages that regulates both inflammation and cellular metabolism.
  • Mice without Gaplinc had slightly pre-armed immune genes and a protective blood-fat balance, and 100 percent survived a lethal bacterial toxin dose.
  • Mice with too much Gaplinc were more prone to rapid, fatal shock.
  • Gaplinc binds to MCCC1, an enzyme inside mitochondria, linking gene expression to metabolic processing.
  • Sepsis kills at least 20 percent of adults and 10 percent of children who develop it, according to the CDC.
  • Any treatment is a research direction only: the team proposes temporary RNA therapies, such as lipid nanoparticles, for acute infection.

What is Gaplinc?

Gaplinc is a long non-coding RNA, or lncRNA: a transcript that makes up a vast portion of the human genome but encodes no protein, instead regulating how genes behave. Gaplinc lives inside macrophages, the white blood cells that act as the body’s first line of defence, engulfing invaders and triggering inflammation. Genetics is moving fast: recent AlphaGenome 2 research mapped DNA changes cell by cell.

The molecule is not new to science: Carpenter’s laboratory first discovered in 2021 that Gaplinc regulates key inflammatory genes driven by a specific protein complex, establishing it as a player in the immune response. The 2026 PNAS study expands that foundation, showing Gaplinc operating across systemic organ networks and metabolic pathways, and connecting the molecule directly to whether an animal survives endotoxic shock, a severe inflammatory reaction to bacterial toxins.

Carpenter, professor of molecular, cell and developmental biology at UC Santa Cruz and co-director of the university’s RNA Center, led the work with co-authors including David Boyd and Camilla Forsberg.

How the dimmer switch works

The team describes Gaplinc as a genetic dimmer switch, or rheostat. A dimmer does not simply turn a light on or off, it sets a level, and Gaplinc appears to set the level of inflammatory activity and cellular metabolism inside immune cells, a level that can decide the outcome of a severe infection.

The mechanism runs through the cell’s energy factories: Gaplinc binds to MCCC1, an enzyme inside mitochondria, bridging gene expression with metabolic processing. A single RNA molecule links what the immune cell’s genes are doing with how the cell burns fuel, reaching into the bloodstream.

When Gaplinc was completely absent in mouse models, baseline immune genes stayed slightly pre-armed before any infection arrived and circulating blood fats shifted into a protective, sepsis-resistant balance. Helpful lipids called lysophosphatidylcholines rose, while toxic free fatty acids fell, and 100 percent of the Gaplinc-deficient mice survived lethal levels of bacterial toxins that proved fatal to normal mice.

The reverse was equally telling: overproduced Gaplinc dropped baseline immune readiness too low, and the mice were much more prone to rapid, fatal shock. Survival depended on the level of Gaplinc: too much left the animal defenceless, none left it protected. That dose-dependent pattern is what makes the dimmer-switch description fit, and it is also what makes the molecule interesting as a target. A treatment would not need to delete Gaplinc permanently; it would need to turn it down, temporarily, at the right moment.

The mouse results, in detail

Gaplinc level Baseline immune readiness Blood fat balance Outcome after lethal toxin
Absent Slightly pre-armed Protective: helpful lipids up, toxic fats down 100 percent survived
Normal Standard Standard Fatal shock
Overproduced Too low Unfavourable Rapid, fatal shock

The experiment used endotoxic shock, in which bacterial toxins trigger the runaway inflammation seen in sepsis. It is a controlled laboratory model, not sepsis as it occurs in a hospital ward, where infections, patients and timing all vary. The 100 percent survival figure is real, and specific to that model; it should not be read as a promise that removing Gaplinc would save every human patient with sepsis.

What the result does show is that a single RNA molecule can decisively change the outcome of a lethal inflammatory challenge, through metabolism as much as immunity. That combination is the new part of the story; earlier sepsis research has largely focused on damping down inflammation directly, an approach that risks leaving patients vulnerable to the infection itself.

Why sepsis is so hard to treat

Sepsis occurs when the immune system overreacts to an infection, triggering runaway inflammation that damages healthy organs, and it can start from common bacterial, viral or fungal infections in the lungs, urinary tract, skin or gastrointestinal tract. Once the cascade begins, existing drugs cannot reliably halt it, and clinicians have few options beyond fluids, antibiotics and supportive care.

According to the Centers for Disease Control and Prevention, sepsis kills at least 20 percent of adults and 10 percent of children who develop it. In the United States, at least 350,000 adults and more than 1,800 children die from sepsis each year during hospitalisation or after transfer to hospice care, and it is present in one out of every three hospital deaths.

“Sepsis is devastating because once that inflammatory cascade spirals out of control, clinicians mostly have to rely on supportive care and hope the patient can weather the storm,” said senior author Susan Carpenter. “Instead of trying to completely shut down the immune system during sepsis, leaving patients vulnerable to the underlying infection, targeting Gaplinc could let us fine-tune the body’s metabolic resilience to survive the shock.”

That framing explains why the discovery matters beyond the laboratory: current treatment supports the patient while the storm passes, while a Gaplinc-based approach would change the conditions that decide whether the storm is survivable at all.

The road to a Gaplinc sepsis treatment

The research team suggests a practical direction: transient RNA therapeutics, such as lipid nanoparticles, could temporarily rebalance Gaplinc levels and reprogram cellular metabolism during acute infection. Lipid nanoparticles are already a proven delivery method for RNA medicines, which makes the idea plausible in principle, but it is a proposal, not a therapy. No Gaplinc treatment has been tested in people, no clinical trial exists, and no timeline has been announced.

Several steps would have to come first: the team must show that temporarily lowering Gaplinc in a living animal, rather than deleting the gene from birth, produces the same protective effect. The human version of the molecule and its role in human macrophages would need confirmation, and any RNA therapy would have to reach the right cells at the right time, during an infection that is already a medical emergency.

For now, the finding belongs to basic science with a clear therapeutic hypothesis attached: a target, a mechanism and a measurable outcome for drug developers. It does not give patients a treatment, and it should not be presented as one.

The limits of the finding

The headline numbers are dramatic, so honest limits matter. First, this is a mouse study: immune and metabolic pathways that behave one way in a mouse do not always behave the same way in a human. Second, endotoxic shock is a model of sepsis, not the full disease; real sepsis comes from many different infections, in patients of many ages and states of health, at many different stages. Third, deleting a gene from birth is not the same as lowering its activity with a drug for a few days, and the protection seen in mice that never had Gaplinc may not appear when Gaplinc is only temporarily reduced.

None of that diminishes the result: a single molecule deciding survival in a lethal model, through a mechanism linking gene expression to metabolism, is a genuine advance in understanding sepsis. Science advances one careful study at a time: a recent analysis of Kuiper Belt dust, published in Science Advances, likewise rested on a small set of samples and stated its limits plainly, and long programmes take patience: Voyager 1, launched in 1977, only recently reached one light-day from Earth. But the distance between this advance and a Gaplinc sepsis treatment is measured in years of further research, and any reporting that skips that distance would mislead readers who may have personal experience of sepsis.

Frequently asked questions

What is Gaplinc?

Gaplinc is a long non-coding RNA molecule found in macrophages, the immune cells that first confront infection. It acts as a genetic dimmer switch, controlling both inflammatory activity and cellular metabolism. UC Santa Cruz researchers discovered in 2021 that it regulates inflammatory genes; their 2026 PNAS study shows it also controls metabolic pathways deciding survival in endotoxic shock.

Does this mean sepsis can now be cured?

No. The study was conducted in mice, and no human treatment exists. Removing Gaplinc helped 100 percent of mice survive lethal bacterial toxin in a controlled laboratory model; a treatment based on the finding would need years of further research and clinical testing.

How is this different from current sepsis treatment?

Current sepsis care is mainly supportive: fluids, antibiotics and care that keeps the patient stable while the immune system fights the infection. The Gaplinc approach would fine-tune the body’s metabolic resilience, turning the molecule down temporarily so the immune system is pre-armed and blood fats sit in a protective balance.

When could a Gaplinc treatment reach patients?

There is no timeline. The team has proposed transient RNA therapies, such as lipid nanoparticles, as a future direction, but no clinical trial has been announced; next are further animal studies and confirmation of the mechanism in human cells.

Where can I read the original research?

The study, “Gaplinc regulates myeloid metabolic pathways in trans in endotoxic shock”, is published in the Proceedings of the National Academy of Sciences (DOI 10.1073/pnas.2616060123); UC Santa Cruz published a news release on 16 November 2026.

Sources and Further Reading